The ventricular assist device (VAD) is used to assist the damaged or weakened heart when pumping blood. This device is surgically attached to one or both of the intact ventricles to aid cardiac circulation.
Key factors contributing to market growth include technological improvements in ventricular assist devices, patient awareness of heart monitoring and treatment options for heart disease management. Moreover, the growing need for medical care in developing and developing world economies is expected to provide an opportunity for market growth. However, a major challenge in the marketplace is the high cost of the VAD process. Bleeding complications and other related risks also impede growth in the ventricular assist device market.
The Asia-Pacific market is projected to grow at the highest CAGR of 14.9% during the forecast period, owing to increase in awareness about the benefits of digital wound measurement devices in healthcare industry and rise in expenditures in emerging markets (such as India and China) to cater to the unmet medical needs.



Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/2024



The major companies profiled in the report are

· Abiomed Inc.

· Asahi Kasei Corporation (Evaheart Medical U.S.A. Inc.)

· Abbott Laboratories (St. Jude Medical Inc.)

· Berlin Heart GmbH

· Calon Cardio-Technology Ltd.

· CardiacAssist Technologies

· Jarvik Heart Inc.

· Medtronic plc

· ReliantHeart Inc.

· Terumo Medical Corporation.


By product, there are LVADs, which account for a significant portion of the global ventricular assistant market in 2016. Bridging applications by application category accounted for more than 49% of the worldwide ventricular assistive devices market in 2016, generating maximum revenue. In addition, the destination treatment segment is expected to witness the highest CAGR of 13.4% during the forecast period. Intentionally implantable ventricular assist devices dominate the market with a share of 3/4 in the worldwide ventricular assistant market in 2016.

Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/2024


Key Findings of the Ventricular Assist Devices Market:
The left ventricular assist devices (LVADs) segment is projected to grow at a significant CAGR of 11.7%, during the forecast period (2017-2023).
Transcutaneous ventricular assist device is projected to grow at a significant CAGR, during the forecast period.
Destination therapy accounted for more than one-fourth share of the global market in 2016.
Germany and France are the major shareholders, and together accounted for more than one-third share of the European market in 2016.
Japan is the major shareholder, accounting for more than one-third share of the Asia-Pacific market in 2016.


Access Full Summery@ https://www.alliedmarketresearch.com/ventricular-assist-devices-market